Deep Brain Stimulation showing promise for patients with mild Alzheimer’s disease over age 65
An age group analysis of data from the ADvance trial has shown that participants over the age of 65 continue to derive the most benefit from Deep Brain Stimulation of the fornix (DBS-f), as observed in the data from the phase 2 findings (12 – 24 months) of the Phase II trial.
The findings, by a team of researchers led by Dr. Andres Lozano at Toronto Western Hospital’s (TW) Krembil Neuroscience Centre (KNC), are the potential beginnings of a patient profile for DBS-f treatment for Alzheimer’s disease. The neurology and psychology aspects of the trial in Toronto were led by TW neurologist Dr. Peter Tang-wai and neuropsychologist Dr. Mary-Pat McAndrews respectively.
To further explore the benefits for this demographic, the research team is soon launching a Phase III, multi-centre international trial that will study the effects of DBS-f in 140 patients over age 65.
Click here to read more.
No upcoming events
Be the first to reply using the above form.